Abstract:The treatment of children with intermediate-risk acute myeloid leukemia in first complete remission has remained controversial. We retrospectively analyzed the outcomes of 80 such children and compared chemotherapy against haploidentical hematopoietic stem cell transplantation after remission. Haploidentical hematopoietic stem cell transplantation resulted in a significantly lower risk of relapse, especially with minimal residual disease of >= 10(-3) after induction therapy. Background: The role of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for children with intermediate-risk acute myeloid leukemia (IR-AML) in first complete remission has been controversial. The present study compared the effect of chemotherapy with unmanipulated haplo-HSCT as treatment of patients with IR-AML in first complete remission (CR1). Patients and Methods: We retrospectively analyzed the outcomes of 80 children with IR-AML and compared the effects of chemotherapy (n = 47) with those of haplo-HSCT (n=33) as treatment in CR1. Results: The 3-year overall survival, event-free survival (EFS), and cumulative incidence of relapse (CIR) was 85.4% +/- 4.1%, 73.2% +/- 5.0%, and 25.4% +/- 4.5%, respectively. Compared with the chemotherapy group, the patients in the haplo-HSCT group had a lower CIR (P = .059) and better EFS (P = .108), but roughly equivalent overall survival (P= .841). Multivariate analysis revealed chemotherapy and minimal residual disease (MRD) of >= 10(-3) after induction therapy as independent risk factors affecting CIR and EFS. EFS (P= .045) and CIR (P = .045) differed significantly between the 2 treatment groups in patients with MRD of >= 10(-3) after induction therapy. Conclusion: Haplo-HSCT might be a feasible option for children with IR-AML in CR1, especially for patients with MRD of >= 10(-3) after induction therapy. (C) 2020 Elsevier Inc. All rights reserved.

Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy As Postremission Treatment of Children with Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.